Article

Influenza Vaccine Efficacy May Be Reduced in Older Adults

Study findings also suggest a path forward to create even more effective flu vaccines.

Influenza vaccines may be less effective in the elderly due to a lack of antibody diversity, according to a new study. However, the findings also suggest a path forward to create even more effective flu vaccines.

The vast majority of influenza-related deaths occur in patients over the age of 65, making it a leading cause of death for the elderly. It is believed that this is due to changes in the immune systems of older patients, but a cross-country team of investigators wanted to find out exactly what was leading to the phenomenon.

The investigators decided to look more closely at B cells, the cells responsible for producing antibodies, to see how they acted differently in young patients and old patients.

According to study results published in the journal Cell Host & Microbe, the authors found that the B cells secreted by elderly patients acquire fewer mutations, rendering them less adept at combating the rapidly changing influenza virus.

While the B cells of young patients mutated in such a way as to be able to tackle new evolutions in the flu virus, study authors found that elderly patients’ B cells were essentially stagnant.

A version of this article was originally published by MD Magazine. Visit MdMag.com to view the full article.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit: Sebastian Kaulitzki | stock.adobe.com
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com